AdaptHealth (AHCO): Customer Relationships and Commercial Profile

AdaptHealth operates a large, vertically integrated home medical equipment and supplies business that monetizes through a mix of per-member-per-month (PMPM) capitation contracts, recurring monthly equipment reimbursements, and one-time spot sales of consumables. The company’s scale—servicing roughly 4.2 million patients across all 50 states—creates a hybrid revenue base that blends recurring contractual cash flows with transactional product sales, while payor mix (government and commercial) and short contract notice periods drive both opportunity and commercial risk. For a concise, actionable view into AdaptHealth’s customer ties and what they imply for investors, read on.
Explore deeper company relationship signals at https://nullexposure.com/.

How AdaptHealth actually makes money — the operating mechanics investors care about

AdaptHealth sells home medical equipment (HME) such as CPAP machines, oxygen concentrators, ventilators, hospital beds and wheelchairs, and it provides related services and recurring supplies such as CPAP masks, wound care and diabetic supplies. Revenue is generated through three principal channels: fixed monthly equipment reimbursements and PMPM fees under capitated arrangements, spot sales for resupply and one-time items, and services delivered directly to patients’ homes. The company reported approximately $3.24 billion in trailing revenue and $586 million in EBITDA, reflecting meaningful gross scale with a mixed margin profile driven by product mix and contractual terms.

Business-model constraints that shape commercial risk and upside

The company-level signals from filings and filings-derived excerpts define several operational characteristics that drive investment conclusions:

• Contracting posture and cash-flow profile: A substantial portion of revenue is derived from PMPM capitation and fixed monthly reimbursements, producing recurring cash flow. At the same time, a meaningful portion of revenue comes from one-time resupply sales, so cash flow is a composite of recurring and transactional streams.
• Contract durability and termination: Most payor contracts are subject to unilateral termination on 30–90 days’ notice, which compresses lock-in and increases churn risk for large payors.
• Counterparty mix and concentration: Government programs (Medicare/Medicaid) represent roughly 26% of net revenue, while individual patients and commercial payors make up the balance—an inherently diverse payor base but one with material exposure to reimbursement policy.
• Revenue concentration by product: Consumables and supplies account for a large share of revenue—approximately 64% of net revenue in 2024—highlighting the company’s dependency on high-frequency, lower-ticket items.
• Geographic scale and maturity: The business is national, operating ~660 locations across 47 states and servicing patients in all 50 states, which indicates a mature distribution footprint and operational complexity.
• Role and delivery model: AdaptHealth acts as both a seller of equipment and a service provider delivering care-at-home solutions; this dual role increases cross-selling opportunities but raises operational execution requirements.

These constraints form the baseline commercial reality for counterparties and investors evaluating AdaptHealth’s customer arrangements.

Customer relationships cited in the record — what’s on file

Below are every relationship entry extracted from the available records. Each entry is summarized in plain English with a source citation.

• HUM (source: AlphaStreet Q2 2025 earnings call transcript — AMP). The company referenced PMPM, capitated arrangements similar to its Humana contract, indicating AdaptHealth operates per-member-per-month agreements with large payors that shift utilization risk and create recurring revenue profiles. Source: AlphaStreet Q2 2025 earnings call transcript (published March 9, 2026) at news.alphastreet.com (AMP).
• Humana (source: AlphaStreet Q2 2025 earnings call transcript — AMP). In testimony, AdaptHealth explicitly compared a PMPM agreement to its Humana capitated contract, signaling an active, structured commercial relationship with Humana that follows capitation economics. Source: AlphaStreet Q2 2025 earnings call transcript (published March 9, 2026) at news.alphastreet.com (AMP).
• HUM (source: AlphaStreet Q2 2025 earnings call transcript — non-AMP). Executive remarks describe a per-member-per-month-type agreement, similar to our Humana contract, reinforcing that AdaptHealth’s commercial model with major insurers includes recurring capitation terms. Source: AlphaStreet Q2 2025 earnings call transcript (published March 9, 2026) at news.alphastreet.com.
• Humana (source: AlphaStreet Q2 2025 earnings call transcript — non-AMP). The earnings call repeats that AdaptHealth supports capitated arrangements, using Humana as an explicit example of that contract form and its associated PMPM billing structure. Source: AlphaStreet Q2 2025 earnings call transcript (published March 9, 2026) at news.alphastreet.com.

What the Humana/insurer relationships imply

AdaptHealth’s repeated public references to Humana-style PMPM capitation make clear that the company pursues risk-aligned, recurring-payor contracts with major insurers. This is material because capitation converts episodic equipment sales into ongoing revenue streams, improves lifetime value per patient, and increases the strategic importance of cost management and care coordination. At the same time, the 30–90 day termination window in most payor contracts places a practical limit on pricing power and increases exposure to near-term renegotiation risk.

Investment implications — where the upside and risks concentrate

• Upside: Recurring PMPM contracts and nationwide scale create a high-leverage profile to utilization improvements and product mix optimization; services + consumables (64% of revenue) provide stable, high-frequency revenue that supports cash conversion. AdaptHealth’s reported EV/EBITDA of ~7.6x and trailing revenue of $3.24B position valuation for multiple expansion if management executes margin improvement.
• Risks: Payor termination notice, reimbursement pressure from government programs (26% of revenue), and dependence on consumables are the primary commercial risks. Short contract notice limits downside protection if payor relationships degrade, and government reimbursement changes would directly impact a large revenue bucket.
• Operational sensitivity: The dual seller/service-provider model creates cross-sell opportunities but requires disciplined logistics and care-delivery execution; any operational failure will compress margins quickly given the mix of low-margin consumables and higher-margin services.

Bottom line for investors and operators

AdaptHealth’s commercial footprint mixes recurring capitation economics with high-volume consumables, producing a revenue profile that is both resilient and exposed to reimbursement and contract-term risk. The explicit linkage to Humana-style PMPM arrangements underscores the company’s strategy to expand recurring revenue streams with major insurers while continuing to monetize consumables and services at scale. Investors should focus on contract renewal timelines, payor mix trends, and margin trends tied to consumables penetration.

For a broader set of signals on counterparties and contract structures across healthcare companies, visit https://nullexposure.com/.

Bold takeaways:

• PMPM capitation is a core commercial lever for AdaptHealth.
• Consumables drive the majority of reported revenue.
• Short contract termination windows increase renegotiation risk despite large scale.